3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Kidney Neoplasms
6
Carcinoma, Renal Cell
6
Pancreatic Neoplasms
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Sarcoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Urethral Neoplasms
2
Ureteral Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Uterine Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Interventions
Abiraterone Acetate
7
enzalutamide
6
olaparib
5
Prednisone
5
Pluvicto
5
Docetaxel
5
radium Ra 223 dichloride
4
darolutamide
4
cabazitaxel
3
Prednisolone
3
testosterone 17 beta-cypionate
2
fludarabine
2
abiraterone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
Genitourinary
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled